Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
20 July 2021Website:
http://www.hcwbiologics.comNext earnings report:
01 April 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 00:59:44 GMTDividend
Analysts recommendations
Institutional Ownership
HCWB Latest News
MIRAMAR, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2024.
This release has made a correction to a release issued under the same headline on August 14, 2024, by HCW Biologics, Inc. (NASDAQ: HCWB), to show the amount included in the condensed interim balance sheet for Cash and cash equivalents as of December 31, 2023 as $3,595,101, not $95,101 as previously stated. The full text of the corrected release is as follows: MIRAMAR, Fla.
MIRAMAR, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2024.
What type of business is HCW Biologics?
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
What sector is HCW Biologics in?
HCW Biologics is in the Healthcare sector
What industry is HCW Biologics in?
HCW Biologics is in the Biotechnology industry
What country is HCW Biologics from?
HCW Biologics is headquartered in United States
When did HCW Biologics go public?
HCW Biologics initial public offering (IPO) was on 20 July 2021
What is HCW Biologics website?
https://www.hcwbiologics.com
Is HCW Biologics in the S&P 500?
No, HCW Biologics is not included in the S&P 500 index
Is HCW Biologics in the NASDAQ 100?
No, HCW Biologics is not included in the NASDAQ 100 index
Is HCW Biologics in the Dow Jones?
No, HCW Biologics is not included in the Dow Jones index
When was HCW Biologics the previous earnings report?
No data
When does HCW Biologics earnings report?
The next expected earnings date for HCW Biologics is 01 April 2025